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  Background:  We hypothesized that, even in patients taking aspirin, the variance of preoperative platelet response 
to collagen might be associated with myocardial injury during coronary artery bypass graft (CABG) surgery.   
Th   erefore, we evaluated the relationship between preoperative whole-blood aggregometry (WBA) by collagen and 
the post  operative myocardial injuries. 
  Methods:  For 44 patients who were scheduled for elective off  -pump CABG and taking aspirin, WBA was measured 
by the impedance method in the presence of collagen (2 mg/ml or 5 mg/ml) as stimulatory agents.  After CABG, 
myocardial injury was evaluated by analysis of the creatine kinase (CK), creatine kinase-MB (CK-MB), and lactate 
dehydrogenase (LD), and by electrocardiography.
  Results:  High response group (n = 13) on preoperative WBA with collagen (2 and 5 mg/ml) showed signifi  cantly 
higher postoperative cardiac enzyme levels (CK, CK-MB and LD) than those of low response group (n = 31). 
  Conclusions:  In patients who take aspirin and undergoing off  -pump CABG, the preoperative platelet response to 
collagen is correlated with postoperative myocardial injury.  (Korean J Anesthesiol 2010; 58: 129-135)
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    The endothelium is crucial to the maintenance of vascular 
physiology and the coagulation system. If the vessels are injured 
and the integrity of the endothelium is lost, platelet is exposed 
to the subendothelial collagen matrix, a potent platelet agonist, 
and become activated [1]. Although this platelet activation is 
basically a protective mechanism to stop bleeding, it may cause 
undesired consequences. The activated platelet may initiate 
the coagulation cascade and release potent vasoconstrictors. 
Consequently, tissue damage may be increased.
    During coronary artery bypass graft (CABG), damage 
to the endo  thelium is difficult to avoid [2], and platelet 
activation in the coronary artery or graft vessels may cause 
fatal complication. Thus, aspirin is administered to prevent 
platelet activation during CABG and aspirin administration in 
early postoperative period is proven to reduce the morbidity 
and mortality in CABG patients [3]. However, 5% to 45% of the 
population is resistant to aspirin [4,5]. Moreover even in non 
resistant patients, aspirin inhibits only the thromboxane A2 
(TxA2)-dependent platelet-activating pathway [6], and the other 
platelet-activating mechanism can still be activated.
    We hypothesized that the variance of preoperative platelet 
response to collagen in patients who take aspirin might be 
associated with platelet activation and consequently modulates 
the myocardial injury during CABG. Therefore, we measured 
whole-blood aggregometry (WBA) with collagen preoperatively 
in off-pump CABG patients taking aspirin, to assess the rela-
tionship with the postoperative myocardial injuries.
.BUFSJBMTBOE.FUIPET
1BUJFOUT
    This study was approved by our institutional ethics 
committee, and written informed consents were obtained from 
all patients. We enrolled adult patients who were scheduled for 
elective off  -pump CABG and who had taken 100 mg of aspirin 
(Bayer Healthcare, Leverkusen, Germany) a day for more than 
a month. The exclusion criteria were the presence of another 
ad  ditional cardiac disease, such as valvular disease, requiring 
surgical treatment prior to heart surgery, known coagulation 
disorders, thrombocytopenia (<150 × 10
9/L), low-molecular-
weight heparin (LMWH) treatment less than 10 days before 
surgery, or any antiplatelet therapy other than aspirin. Patients 
with uncontrolled hypertension, alcoholism, heavy smoking, 
psychiatric illness, renal disease (Cr > 177 μmol/L), or active 
liver disease were also excluded.
5SFBUNFOUBOETVSHJDBMQSPDFEVSFT
    The preoperative aspirin medication (100 mg a day in the 
morning) was continued until two day before surgery. From 
postoperative day 1, the patients were recommended to take 
aspirin.
    For all the patients, anesthetic and surgical techniques 
were standardized. Anesthesia was induced with midazolam, 
etomidate, and sufentanil, and maintained with midazolam, 
sufentanil, and vecuronium by continuous intravenous infusion. 
During operation, intravenous fluids and dobutamine were 
titrated to maintain cardiac index and mean arterial pressure 
at a minimum of 2.2 L/min/m
2 and 65 mmHg, respectively. If 
hypotension developed with adequate cardiac index and pul-
monary capillary wedge pressure (>10 mmHg), intravenous 
norephinephrine (0.05 μg/kg/min to 0.2 μg/kg/min) was admi-
ni stered.
    After the pericardium was opened, heparin was administered 
at a dose of 300 unit/kg, and an activated coagulation time 
(ACT) greater than 300 s was maintained with supplementary 
doses of heparin until the completion of anastomoses. The 
surgical technique for CABG was the off  -pump technique with 
a stabilizer (Octopus
⡴2+ Tissue Stabilization System, Medtronic 
Inc., Minneapolis, MN, USA) and an intracoronary shunt. 
After the completion of revascularizaton, the heparin effect 
was not reversed with protamine sulfate. For all the patients in 
our study with intraoperative bleeding, a cell separator (Cobe 
BRAT 2, Cobe Cardiovascular Inc., Arvada, CO, USA) was used 
to concentrate the lost blood, and this blood was reinfused. All 
patients had mediastinal and pleural drains.
8IPMFCMPPEJNQFEBODFBHHSFHPNFUSZ	8#"
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    Platelet aggregation was studied in the presence of two 
diff  erent doses of collagen (2 μg/ml or 5 μg/ml) as stimulatory 
agents with the impedance method using whole-blood aggre-
gometry (Chrono-Log 592, Chrono-Log Corp., Havertown, PA, 
USA). One day before surgery, blood samples were collected 
by sterile venipuncture from the antecubital fossa using a 
21-gauge butterfl  y needle. Samples were transferred into poly-
propylene tubes containing 0.5 ml of 3.2% (w/v) sodium citrate. 
Measurements of whole-blood platelet aggregation were made 
according to the Chrono-Log protocol [7]. Briefl  y, whole blood 
diluted 1 : 1 with 0.85% (w/v) saline was incubated with the 
appropriate antagonist, then supplemented with collagen (2 
μg/ml or 5 μg/ml). The impedance value reflecting the extent 
of platelet aggregation was read after 6 min. Th  e  patients  who 
showed the WBA values in upper 30% were defined as high 
response group and the other lower 70% patients were defi  ned 131 www.ekja.org
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as low response group. 
$BSEJBDFO[ZNFT
    Blood was sampled for the measurement of creatine kinase 
(CK, reference range 20-270 IU/L), creatine kinase-MB (CK-
MB, reference range 0-24 IU/L), and lactate dehydrogenase 
(LD, reference range 100-225 IU/L) immediately before surgical 
incision (T1), at the end of the operation (T2), 6 hours (T3), 1 
(T4), 2 (T5), 3 (T6), and 5 days (T7) after the operation.
&MFDUSPDBSEJPHSBNT
    Twelve-lead electrocardiograms were obtained at the end 
of the operation, 1, 2, 3, and 5 days after the operation. All 
electrocardiograms were read and agreed upon by two car-
diologists blinded to the patient's clinical course and car-
diac enzyme concentrations. Cardiac events measured by 
electrocardiographic criteria were classified as one of the 
following: (1) persistent new Q waves (≥40 ms) occurring in 
at least two leads; (2) persistent new R waves (≥40/50 ms) 
occurring in V1/V2, in more than two leads; and (3) new-onset 
complete bundle branch block.
1PTUPQFSBUJWFCMFFEJOH
    Chest tube outputs were assessed at 8 and 24 hours after 
surgery to measure postoperative bleeding. The chest tube 
outputs were calculated from the contents in the water-seal 
chest drainage system.
4UBUJTUJDBMBOBMZTJT
    Continuous variables are presented as means ± SD. 
Categorical variables are presented as frequencies and 
percentages. Un  paired t or Rank Sum test (if not normally 
distributed) were used to compare the demographic, clinical 
variables and the postoperative parameters (cardiac enzymes) 
at each time point between the 2 groups. The correlation 
between variables was assessed by Pearson’s correlation. A 
Table 1. Demographic and Clinical Characteristics
Variable
Collagen 2 μg/ml
P value
Collagen 5 μg/ml
P value High response 
group (n = 13)
Low response 
group (n = 31)
High response 
group (n = 13)
Low response 
group (n = 31)
Age, yr 63.9 ± 10.5 63.0 ± 8.6 0.762 65.3 ± 8.58 62.5 ± 10.3 0.563
Male sex, % 69.2 80.6 0.561 69.2 80.6 0.561
One-vessel disease, % 0 0 0.990 0 0 0.990
Two-vessel disease, % 15.3 19.4 0.846 15.4 19.4 0.846
Th   ree-vessel disease, % 84.6 80.6 0.846 84.6 80.6 0.846
Normal left ventricular function, % 61.5 41.9 0.471 61.5 45.2 0.842
LVEF, % 56.5 ± 15.4 50.9 ± 10.8      0.1 55.3 ± 13.5 53.7 ± 9.8       0.42
Preoperative Hb, g/dl 12.4 ± 0.7 12.4 ± 1.13  0.850 12.4 ± 1.0 12.2 ± 1.2 0.394
ASA class II, III % 100 100 0.990 100 100 0.990
CCS class I or II, % 84.6 93.5 0.211 84.6 93.5 0.211
CCS class III or IV, % 15.4   6.5 0.211 15.4   6.5 0.211
Previous MI, % 23.1 41.9 0.333 23.1 41.9 0.333
Smoking, % 38.5 54.8 0.402 30.8 58.1 0.160
Hypertension, % 38.5 35.5 0.887 53.8 35.5 0.201
Hypercholsterolemia, %   7.7 29.0 0.272 7.7 29.0 0.272
Diabetes mellitus, % 84.6 48.4 0.061 69.2 54.8 0.462
CVA history, % 15.4 0 0.433 15.4 0 0.433
COPD, %    7.7 6.4 0.154   7.7   9.6 1.000
Number of anastomoses 3.0 ± 0.8 3.0 ± 1.0 0.807 3.2 ± 0.7 2.9 ± 1.0 0.146
Postoperative Hb, g/dl 9.3 ± 0.6 9.4 ± 0.7 0.574 9.5 ± 0.5 9.3 ± 0.7 0.285
Time to extubation, hr 14.2 ± 4.8 13.8 ± 4.9 0.774 14.7 ± 4.8 12.6 ± 4.3 0.183
Data are presented as mean ± SD or percentage of patients. Normal ventricular function means that left ventricular ejection fraction is more 
than 55%. MI: myocardial infarct,  ASA: American Society of Anesthesiologists,  CCS: Canadian Cardiovascular Society, CVA: Cerebro-vascular 
accident.132 www.ekja.org
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P value of < 0.05 was considered statistically signifi  cant. In our 
pilot study, LD level of low response group was 250 ± 53 IU/L in 
2 μg/ml and 265 ± 58 IU/L in 5 μg/ml at postoperative 3 day. We 
expected 50% increase of LD in high response group. A sample 
size of at least 5 patients was needed in both 2 μg/ml and 5 μg/
ml group, to obtain a power of 0.8 with two sided alpha value of 
less than 0.05. Analyses were performed using SigmaStat ver.3.1 
(Systat Software Inc., Chicago, IL, USA) and SPSS ver.12.0 (SPSS 
Inc., Chicago, IL, USA).
Table 2. Th   e Platelet Aggregometry Data 
Stimulating agent
Impedance (Ω)
High response group 
(n = 13)
Low response group 
(n = 31)
Collagen 2  μg/ml     18 ± 1.32 8.84 ± 3.87
Collagen 5  μg/ml 24.2 ± 2.99 13.5 ± 3.88
Values are presented as mean ± SD. 
Fig. 1. Cardiac enzyme at immediately before surgical incision (T1), at the end of the operation (T2), and 6 h (T3), 1 (T4), 2 (T5), 3 (T6), and 5 
day (T7) for the low and high response groups by the collagen 2 (A) and 5 (B) μg/ml on whole blood aggregometry. LD: lactate dehydrogenase 
isoenzyme, CK: creatine kinase, MB: creatine kinase MB fraction, High: high response group, Low: low response group. *P < 0.05 between low 
and high response groups.133 www.ekja.org
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    Forty-four patients were enrolled in this study and completed 
the trial. No deaths or serious adverse events were reported over 
the treatment period. Demographic and clinical characteristics 
of high and low respond groups for 2 and 5 μg/ml collagen 
WBA are shown in Table 1. Among 44 patients, 13 and the other 
31 patients were classified as high and low response groups 
respectively.
8IPMFCMPPEJNQFEBODFBHHSFHPNFUSZGPSQMBUFMFU
BHHSFHBUJPO
    Th   e platelet aggregation data are presented in Table 2.
$BSEJBDFO[ZNFT
    High response group on low dose (2 μg/ml) collagen WBA 
showed higher LD on postoperative 1, 3 and 5 days (P values = 
0.012, <0.001 and <0.001 respectively), CK on postoperative 1, 
5 days (P values = 0.027 and 0.009 respectively) and CK-MB on 
postoperative 5 day (P value = 0.004) than low response group. 
High response group on high dose (5 μg/ml) collagen WBA also 
showed higher LD (postoperative 3 and 5 days with P values of 
0.004 and 0.002 respectively), CK (postoperative 1, 2, 3 and 5 
days with P values of 0.027, 0.007, 0.005 and 0.001 respectively) 
and CK-MB (postoperative 2, 3 and 5 days with P values of 
0.019, 0.001 and <0.001) than low response group. On high 
dose collagen WBA, there was no diff  erence between low and 
high response groups on preoperative cardiac enzyme levels. 
However, on low dose collagen aggregometry, high response 
group showed higher LD and CK levels (P values = 0.009 and 
0.028 respectively) (Fig. 1) than low response group. 
$PSSFMBUJPOCFUXFFOWBSJBCMFT
    Fig. 2 illustrates the relationship between CK-MB, CK and LD 
at 3 day after operation. A signifi  cant correlation was found only 
between CK-MB and CK (r = 0.699, P < 0.001). 
Fig. 2. Relation between CK-MB , CK and LD at 3 day after operation. r, 
Pearson’s correlation coeffi   cient.134 www.ekja.org
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Table 3. Postoperative Bleeding Assessed by Chest Tube Drain 
1-8 h P value 1-24 h P value
Collagen High response group 1,031.5 ± 449.4 0.391     1,420 ± 612.9 0.169
2 ug/ml Low response group     852.1 ± 258.7 1,145.5 ± 309.5
Collagen High response group 1,019.2 ± 405.6 0.205 1,355 ± 564 0.234
5 ug/ml Low response group     844.3 ± 294.4 1,156 ± 373
Values are chest tube output (ml) and presented as mean ± SD.
1PTUPQFSBUJWFCMFFEJOH
    Th   ere was no signifi  cant diff  erence on postoperative bleeding 
between two groups (Table 3).
&MFDUSPDBSEJPHSBQIJDBOBMZTJT
    Th   ere was no demonstrated electrocardiographic evidence of 
a new post-CABG cardiac event in any of the 44 patients with 
assessable electrocardiograms.
%JTDVTTJPO
    This study shows that high response to collagen on pre-
operative WBA is associated with increased perioperative myo-
cardial injury in the patients undergoing off  -pump CABG even 
if they take aspirin. 
    Th   e clinical importance of endothelial damage during CABG 
is well known, and measures are taken to prevent endothelial 
damage. However, even when the ‘no-touch technique’ is used, 
injury to the endothelium is difficult to avoid [2]. Damaged 
endothelium exposes the subendothelial collagen, a platelet 
agonist, and activated platelet generates microemboli, which 
may be an important mechanism of myocardial injury [8]. In 
addition, during carotid endarterectomy, preoperative platelet 
aggregation induced with collagen was significantly higher in 
patients with more microemboli on intraoperative transcranial 
doppler monitoring [9]. The other studies have stressed that 
coronary spasm induced by TxA2 released from activated 
platelet is an important mechanism underlying the myocardial 
injury caused by activated platelet [10,11].
    Aspirin inhibits platelet cyclooxygenase (COX)-1, which con-
verts arachidonic acid to TxA2 [4,12]. TxA2 activates the pla-
telet TxA2 receptor. Thus, aspirin activity is usually reflected 
in the platelet response to arachidonic acid. In addition, the 
aspirin effect can also be detected using low and high dose 
collagen WBA. In low dose collagen WBA, only normal platelets 
aggregate, whereas in high dose collagen WBA, both normal 
and aspirin-inhibited platelets aggregate [13]. In this study, 
both low and high dose of collagens were used as platelet 
ago  nists. The result that high responders on low dose WBA 
showed higher myocardial injuries can be explained by aspirin 
resistance. However, considering the previously reported rate 
of aspirin resistance [14], the number of patients in our study 
is not suffi   cient to cause the diff  erence between groups on low 
dose collagen WBA by the aspirin resistance alone. Moreover, 
there were diff  erences on the preoperative myocardial enzyme 
levels between low and high responders on low dose collagen 
WBA (Fig. 1). Therefore in this study the results by low dose 
collagen aggregometry might be infl  uenced by not only aspirin 
resistance but also the difference of the preoperative disease 
activity expressed on both baseline myocardial enzyme and low 
dose collagen aggregometry.
    The preoperative variance of high dose WBA values in our 
study could have refl  ected a polymorphism in platelets or been 
related to the variously activated state of the platelets. Either 
way, this study showed that the preoperative variations in the 
platelet response to collagen correlated with postoperative 
myocardial injury during CABG. Consequently, it stresses 
the importance of collagen-mediated platelet activation on 
myocardial injury during CABG and suggests the potential role 
of blocking the receptor for protective strategy. Although several 
receptors have been proposed as platelet collagen receptors, 
glycoprotein VI (GPVI) has recently received considerable 
attention. Mouse or human platelets in which GPVI has 
been pharmacologically blocked or immunodeleted are 
unresponsive to collagen [15]. Collagen signaling is conferred by 
the expression of GPVI in hematopoietic cell lines that express 
its coreceptor FcRg [16]. This suggests that GPVI signaling is 
both necessary and suffi   cient for the activation of platelets by 
collagen under conditions of abundant receptors and ligands. 
Studies with mice have shown that GPVI-deficient mice 
display a nearly complete abolition of the platelet response to 
endothelial injury [17].
    Moreover, GPVI-deficient mice do not exhibit an overt 
bleeding phenotype and that GPVI-deficient humans show 
only minor bleeding diatheses rather than major bleeding 
phenotypes. Th   is is consistent with the observation in this study 
that collagen WBA only correlated with myocardial injury and 
not with blood loss after CABG. Considering the preoperative 
use of platelet inhibitors, such as aspirin, may increase 
postoperative bleeding, potential importance of collagen 135 www.ekja.org
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receptor block during CABG is more stressed. 
    In conclusion, this study demonstrates that even in patients 
taking aspirin who undergo off  -pump CABG, the preoperative 
platelet response to collagen correlates with postoperative 
myocardial injury. Th   is emphasizes the importance of collagen-
mediated platelet activation during CABG.
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